6976:TSETaiyo Yuden Co., Ltd. Analysis
Data as of 2026-06-09 - not real-time
¥17,975.00
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Taiyo Yuden is trading at its 52‑week high of ¥17,975 with an RSI of 81.8, indicating a strongly overbought condition, while the MACD remains bullish and volume is on an increasing trend, supporting the current bullish momentum. However, the price sits at a key resistance level of ¥17,975, the beta is above 1.1 and 30‑day volatility exceeds 100%, suggesting the stock is vulnerable to a sharp pull‑back, especially given the recent max drawdown of about 30%.
Fundamentally, the company posted ¥355 bn in revenue with modest 2.9% growth and thin margins (gross 23%, operating 3.7%). Valuation is extreme: a trailing P/E of 138.9 versus an industry average of 35.6, and a P/B of 6.5, while analyst targets cluster around ¥5,400–¥6,200, implying a substantial upside‑downside gap. The dividend yield is only 0.6% with an 84% payout ratio and limited free cash flow, raising concerns about dividend sustainability. Recent news cites recovery in MLCC orders and margin‑expansion initiatives, which could improve profitability, but the current price appears dramatically overvalued relative to fundamentals.
Fundamentally, the company posted ¥355 bn in revenue with modest 2.9% growth and thin margins (gross 23%, operating 3.7%). Valuation is extreme: a trailing P/E of 138.9 versus an industry average of 35.6, and a P/B of 6.5, while analyst targets cluster around ¥5,400–¥6,200, implying a substantial upside‑downside gap. The dividend yield is only 0.6% with an 84% payout ratio and limited free cash flow, raising concerns about dividend sustainability. Recent news cites recovery in MLCC orders and margin‑expansion initiatives, which could improve profitability, but the current price appears dramatically overvalued relative to fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- RSI overbought and price at resistance
- Bullish MACD but high short‑term volatility
- Limited upside given extreme valuation
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- P/E far above industry peers
- Analyst target prices imply >60% downside
- Modest earnings growth and high debt levels
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Strong market position in MLCCs and order recovery
- Potential margin expansion from restructuring
- Valuation gap may correct over a multi‑year horizon
Key Metrics & Analysis
Financial Health
Revenue Growth2.90%
Profit Margin4.17%
P/E Ratio138.9
ROE4.46%
ROA2.05%
Debt/Equity49.71
P/B Ratio6.5
Op. Cash Flow¥58.1B
Free Cash Flow¥600.1M
Industry P/E35.6
Technical Analysis
TrendBullish
RSI81.8
Support¥6,302.00
Resistance¥17,975.00
MA 20¥11,760.55
MA 50¥7,987.48
MA 200¥4,698.10
MACDBullish
VolumeIncreasing
Fear & Greed Index85.3
Valuation
Target Price¥6,168.67
Upside/Downside-65.68%
GradeOvervalued
TypeValue
Dividend Yield0.60%
Risk Assessment
Beta1.20
Volatility101.99%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.